Cyrus technology can speed new drug discovery
SEATTLE, WA November 20, 2017 — Cyrus Biotechnology, a biotechnology software company offering first-in-class tools for advanced protein modeling and discovery in drug development, announced today that it has appointed David Pearlman, Ph.D. as Senior Fellow and Director of Customer Experience. Dr. Pearlman will lead scientific customer interactions with Cyrus’s client firms in pharmaceuticals, biotechnology therapeutics, synthetic biology and consumer products, creating a unified customer experience team. Dr. Pearlman’s team will guide users towards creating enhanced value through new engineered proteins and other compounds for a wide variety of indications using Cyrus technology. Prior to joining Cyrus, Dr. Pearlman’s industry role was Senior Scientist and Director of Biologics Software Platform at Schrödinger, LLC, a leader in chemical simulation software and services.
“David has a track record of scientific innovation and market-savvy product creation in molecular modeling software that is unique. We are very fortunate to add him to our leadership team at Cyrus”, said Dr. Lucas Nivon, CEO of Cyrus. “He has played a critical role in the creation and growth of a number of innovative and market-leading firms, and has the unique blend of deep scientific understanding and customer-centric product development that will be important for Cyrus as we engage with a rapidly expanding set of customers.”
“The ability of computational chemistry to make significant contributions to molecular discovery has grown tremendously over my career.” said Dr. Pearlman. “We’re now at a point where understanding, methods and computational resources are having real, measurable impact on new drug discovery. I’m particularly excited to be at Cyrus, where we are commercializing the world-class Rosetta protein design tools. The Rosetta platform has been at the heart of an incredible number of defining protein design studies over the past couple of decades.” Pearlman added.
Dr. Pearlman is a pioneer in the field of computational chemistry. He was a founding product manager at Biosym Technologies (later BIOVIA), an early employee of Vertex Pharmaceuticals, and led development of the biologics software platform (BioLuminate) at Schrödinger, LLC. He was also, for many years, first author and a principal developer of the widely-used AMBER simulation platform. He has published a long string of seminal papers in the area of free energy perturbation, and extensively on topics such as NMR refinement and de novo ligand design and scoring.
Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus is funded by experienced investors in Tech and Biotech including Trinity Ventures, Orbimed Advisors, SpringRock Ventures, W Fund and others…
NOTICE: The information contained in this document is dated as of November 20, 2017. Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date. This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Contact Lucas Nivon